4/11
08:10 am
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
High
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
4/10
09:32 am
omer
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program [Yahoo! Finance]
Medium
Report
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program [Yahoo! Finance]
4/10
09:10 am
omer
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
Medium
Report
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
4/9
02:31 am
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/8
09:00 am
omer
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
Medium
Report
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
4/1
11:03 pm
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/1
12:46 pm
omer
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/1
08:00 am
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
3/31
04:17 pm
omer
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results [Yahoo! Finance]
Medium
Report
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results [Yahoo! Finance]
3/31
04:02 pm
omer
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
Medium
Report
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
3/26
09:15 am
omer
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
Medium
Report
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
3/21
03:39 pm
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Low
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
3/21
09:46 am
omer
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program [Yahoo! Finance]
Low
Report
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program [Yahoo! Finance]
3/21
09:15 am
omer
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Low
Report
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
3/21
02:03 am
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/13
08:07 pm
omer
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company's OMS527 Program to Treat Cocaine Use Disorder [Yahoo! Finance]
Medium
Report
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company's OMS527 Program to Treat Cocaine Use Disorder [Yahoo! Finance]
3/13
09:00 am
omer
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
Low
Report
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
3/13
02:08 am
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/5
11:06 pm
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/20
05:46 pm
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
2/20
09:39 am
omer
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA [Yahoo! Finance]
Low
Report
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA [Yahoo! Finance]
2/20
09:10 am
omer
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Low
Report
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
2/14
09:00 am
omer
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Low
Report
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
2/10
09:54 am
omer
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program [Yahoo! Finance]
Low
Report
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program [Yahoo! Finance]
2/10
09:00 am
omer
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Low
Report
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program